Compare FAST & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAST | ZTS |
|---|---|---|
| Founded | 1967 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2B | 54.8B |
| IPO Year | N/A | 2013 |
| Metric | FAST | ZTS |
|---|---|---|
| Price | $43.26 | $124.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $46.13 | ★ $166.60 |
| AVG Volume (30 Days) | ★ 9.6M | 4.6M |
| Earning Date | 01-20-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.21% | 1.70% |
| EPS Growth | 9.00 | ★ 11.64 |
| EPS | 1.09 | ★ 5.94 |
| Revenue | $8,200,500,000.00 | ★ $9,397,000,000.00 |
| Revenue This Year | $11.64 | $3.04 |
| Revenue Next Year | $8.29 | $4.94 |
| P/E Ratio | $39.78 | ★ $21.03 |
| Revenue Growth | ★ 8.67 | 2.68 |
| 52 Week Low | $35.31 | $115.25 |
| 52 Week High | $50.63 | $177.40 |
| Indicator | FAST | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 50.23 |
| Support Level | $43.38 | $121.25 |
| Resistance Level | $44.13 | $126.29 |
| Average True Range (ATR) | 1.08 | 2.86 |
| MACD | -0.01 | -0.27 |
| Stochastic Oscillator | 54.69 | 62.90 |
Fastenal began as an industrial retailer, expanding its product portfolio from nuts and bolts to cutting tools, safety equipment, and janitorial supplies. It transitioned into a distributor by building out a dense network of branches close to its business customers. Once a customer becomes large enough, Fastenal installs vending machines and its own personnel on-site. Today, these on-site locations exceed Fastenal's branch count and remain the firm's main focus for expansion. Fastenal acts as a one-stop outsourcing partner for its industrial customers, offering value-added services along with a wide breadth of maintenance, repair, and operations supplies.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.